

Ref : JPL/CS/1457/2017.

Date : 12<sup>th</sup> October, 2017.

To  
The BSE Ltd.  
Phiroze Jeebhoy Towers ,  
Dalal Street ,  
Mumbai - 400 023.

Sub.: Details of Compliants received from the Investors for the quarter ended on 30<sup>th</sup> September, 2017.

Ref.: Regulation 13(3) of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Stock Code : 524731


Dear Sir / Madam,

Kindly find enclosed a statement under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, giving the details of complaints received from Investors', their disposal during the quarter from 1<sup>st</sup> July, 2017 to 30<sup>th</sup> September, 2017.

You are requested to take on record the same and acknowledge receipt.

Thanking you,

Yours faithfully,  
For JENBURKT PHARMACEUTICALS LTD.,



ASHISH SHAH  
Company Secretary.

Encl.: As stated above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

**Statement under Regulation 13(3) of SEBI (Listing Obligation  
and Disclosure Requirements) Regulations, 2015, for the  
Quarter ended on 30<sup>th</sup> September, 2017**

Particulars	30/09/2017
<b>Investors' Complaints</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	02
Disposed of during the quarter	02
Remaining unsolved at the end of the quarter	NIL

For Jenburkt Pharmaceuticals Limited



Ashish R. Shah  
(Company Secretary)